Identifying different types of inflammatory Th17 cells using a specific inhibitor
Distinguishing inflammatory Th17 subsets through using an autoimmune Th17-selective inhibitor
This study is looking at a type of immune cell called Th17 cells to find a way to reduce their harmful effects in autoimmune diseases while still keeping their ability to help fight infections, which could lead to better treatments for people with these conditions.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Southern California NIH-funded |
| Lab location | 1 site (Los Angeles, UNITED STATES) |
| Project ID | NIH-10814571 on NIH RePORTER |
What this research studies
This research focuses on understanding Th17 cells, which are important in autoimmune diseases affecting millions of Americans. The project aims to differentiate between harmful inflammatory Th17 cells and those that help fight infections. By using a selective inhibitor, the researchers hope to suppress the autoimmune functions of these cells without compromising their ability to combat infections. This approach could lead to new treatment strategies for autoimmune conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from autoimmune diseases that involve Th17 cells.
Not a fit: Patients with autoimmune diseases not involving Th17 cells or those who do not respond to Th17-targeted therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for autoimmune diseases with fewer side effects.
How similar studies have performed: Previous research has shown promise in targeting Th17 cells for autoimmune diseases, indicating that this approach may lead to significant advancements.
Where this research is happening
Los Angeles, UNITED STATES
- University of Southern California — Los Angeles, United States (Active)
Researchers
- Principal investigator: He, Zhiheng — University of Southern California
- Study coordinator: He, Zhiheng
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.